Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Evoxac

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
Cevimeline (Evoxac ®) is an oral muscarinic agent that has been recently approved for the treatment of xerostomia in the setting… Expand
Is this relevant?
2009
2009
OBJECTIVE The aim of the present study was to compare the effect of low-dose pilocarpine and cevimeline as stimulants for… Expand
Is this relevant?
2007
2007
Muscarinic M3 receptors exist in the gastrointestinal wall in humans and the muscarinic M3 agonist cevimeline hydrochloride… Expand
Is this relevant?
2004
2004
Irrigation of the salivary gland using a corticosteroid is one of the most successful approaches to improving xerostomia in… Expand
Is this relevant?
Review
2003
Review
2003
M1 muscarinic receptors (M1 mAChRs) play a role in an apparent linkage of three major hallmarks of Alzheimer’s disease (AD… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2002
2002
The M1 muscarinic agonists AF102B (Cevimeline, EVOXACTM: prescribed in USA and Japan for Sjogren’s Syndrome), AF150(S) and AF267B… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2000
2000
  • The Medical letter on drugs and therapeutics
  • 2000
 
Is this relevant?